1 |
Hubert S, Renana S, Hedi G, Markus N, Heinrich W, Winfried M. 2001. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochemical Pharmacology 62: 1545-1555.
DOI
ScienceOn
|
2 |
Endo A, Negishi Y, Iwashita T, Mizukawa K, Hirama M. 1985. Biosynthesis of ML-236B (compactin) and monacolin K. J Antibiot 38: 444-448.
DOI
|
3 |
Soheil N, Rune B, June M, Erlend BS, Bjorn E, Kaare RN, Heidi KB. 1999. Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosis. Experimental Cell Research 252: 144-153.
DOI
ScienceOn
|
4 |
Endo A, Kuroda M, Tarazawa K. 1976. Competitive inhibitor of 3-hydroxy-methylglutaryl-coenzyme A reductase by MC-230A and ML-236 B fungal metabolites having hypocholesterolemic activity. FEBS Lett 72: 323-326.
DOI
ScienceOn
|
5 |
Domsch KH, Gams W. 1980. Compendium of soil fungi. Academic press, London. Vol 1, p 114-117.
|
6 |
Tobert JA. 1988. Efficacy andlLong-term adverse effect pattern of lovastatin. J American Cardiology 62: 28-34
|
7 |
Matilde M, Silvia B, Manuela R, Valeria C. 1999. Production of statins by filamentous fungi. Biotechnology 21: 253-257.
|
8 |
Michael HD, Peter L, Jim XS, Gale P, Edward W, Arnold S, Robert N, Lawrence F. 2002. A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended and immediate-release formulations of lovastatin. Clinical Therapeutics 24: 112-125.
DOI
ScienceOn
|
9 |
Srinivasu MK, Narasa RA, Om RG. 2002. Determination of lovastatin and simvastatin in pharmaceutical dosage forms by MEKC. J Pharmaceutical and Biomedical Analysis 29: 715-721
DOI
ScienceOn
|
10 |
Casas Lopez JL, Sanchez Perez JA, Ferenandez Sevilla JM, Acien Fernandez FG, Molina Grima E, Chisti Y. 2003. Production of lovastatin by Aspergillus terreus : effects of the C:N ratio and the principal nutrients on growth and metabolite production. Enzyme and Microbial Technology 33:
270-277.
DOI
ScienceOn
|
11 |
Gyorgy Szakacs, Gyorgy Morovjan, Robert PT. 1998. Production of lovastatin by a wild strain of Aspergillus terreus. Biotechnology Lett 20: 411-415.
DOI
ScienceOn
|
12 |
Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Alberts-Schonbert G, Hensens O, Hirshfield J, Hoogsteen K, Leish J, Springer J. 1980. Mevinolin: a highly protent competetive inhibitor of hydroxy-methylglutaryl-coenzyme, A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci 77: 3957-3961.
DOI
ScienceOn
|
13 |
Yu TS, Kim J, Kim HS, Hyun JS, Ha HP, Park MG. 1998. Bibliographical study on microorganism of traditional Korea nuruk (since 1945). J Korean Soc Food Sci Nutr 27: 789-799.
|
14 |
Slater EE, Macdonald JS. 1988. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 36: 72-82.
DOI
|
15 |
Kumar MS, Kumar PM, Sarnaik HM, Sadhukhan AK. 2000. A rapid technique for screening of lovastatin-producting strains of Aspergillus terreus by agar plug and Neurospora crassa bioassay. J Microbiological Methods 40: 99-104.
DOI
ScienceOn
|
16 |
Brown MS, Faust JR, Goldsten JL, Kaneko I, Endo A. 1978. Induction of 3-hydroxy-methylglutaryl-coenzyme, A reductase activity in human firboblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 253: 1121-1128.
|
17 |
Endo A. 1985. Compactin (ML-236B) and related compound as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J Med Chem 28: 401-405.
DOI
|
18 |
Finkelstein DB, Ball C. 1992. Biotechnology of filamentous fungi. Butterworth-Heineman, London, UK. p 241-251.
|